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1  | INTRODUC TION
The ever-increasing advances in genomic sequencing have facil-
itated the sequencing of disease-associated genes and in particu-
lar, those associated with disorders of haemostasis. The task of 
reporting and analysing DNA variants is a major challenge. There are 
currently two types of repositories for these variants. First, central 
databases contain pooled information on variation across the whole 
genome. These resources generally contain a list of known genetic 
variants but less frequently provide detailed information or analyses 
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Abstract
Introduction: Advances in genomic sequencing have facilitated the sequencing of genes 
associated with disorders of haemostasis. The identification of variants within genes 
and access to curated data incorporating structural, functional, evolutionary as well as 
phenotypic data has become increasingly important in order to ascribe pathogenicity.
Aim: The European Association for Haemophilia and Allied Disorders (EAHAD) 
Coagulation Factor Variant Database Project aims to provide a single port of entry to 
a web-accessible resource for variants in genes involved in clinical bleeding disorders.
Results: New databases have evolved from previously developed single gene variant 
coagulation database projects, incorporating new data, new analysis tools and a new 
common database architecture with new interfaces and filters. These new databases 
currently present information about the genotype, phenotype (laboratory and clini-
cal) and structural and functional effects of variants described in the genes of factor 
(F) VII (F7), FVIII (F8), FIX (F9) and von Willebrand factor (VWF).
Conclusion: The project has improved the quality and quantity of information avail-
able to the haemostasis research and clinical communities, thereby enabling accurate 
classification of disease severity in order to make assessments of likely pathogenicity.
K E Y W O R D S
blood coagulation factors, factor VII, genotype, haemophilia A, haemophilia B, von Willebrand 
factor
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that help predict the impact of variations on the structure, function 
and stability of the specific protein expressed by the gene associ-
ated with the disease. None of these central databases contain all 
the tools required for full clinical interpretation of variants. Second 
by contrast, gene variant databases, also known as locus-specific da-
tabases (LSDBs), that collect and display information on sequence 
variants (mutations) on a gene-by-gene basis are usually run by a 
consortium of collaborating researchers with scientific expertise in 
a particular gene or phenotype. LSDBs provide an invaluable tool 
for analysing variants, generally promoting submission of data and 
therefore enabling an accurate and up-to-date resource. Complete 
and up-to-date variant databases save valuable user time and stimu-
late effective diagnosis and research by providing access to curated 
standardized and annotated data, which would otherwise be scat-
tered over many different resources. Importantly, the curators check 
the data entered into the database, which increases data quality, as 
there are a significant number of reporting errors in published arti-
cles. In addition, LSDBs provide access to variant information that 
has been collected by direct database submission and would not 
otherwise be available as it becomes increasingly difficult to pub-
lish variant data. With the advent of next-generation sequencing of 
ever-increasing numbers of individuals and therefore increased iden-
tification of variants within genes, access to curated data incorpo-
rating structural, functional, evolutionary as well as phenotypic data 
becomes increasingly important in order to ascribe pathogenicity.
Locus-specific databases for haemostatic genes were first estab-
lished with the publication of collated data for variants in F9,1 F82 
and VWF3 in the early 1990s. The first web-based database for F8 
appeared in 1996.4 Over the years, several additional coagulation 
factor variant databases have also been developed (F7,5 F10, F116 
and fibrinogen [FGA, FGB, FGG]7). Some allowed database search-
ing and provided a number of additional resources, whereas others 
offered data in a downloadable Excel spreadsheet. These resources 
provided an invaluable resource to the haemostasis community and 
were highly cited. However, many of these databases were estab-
lished and maintained by individuals and availability of time and 
funding had a significant impact on their ability to maintain the data-
base as well as continuity of access to a stable URL. An LSDB loses 
its relevance once it is not maintained and updated on a regular basis.
In response to these concerns, the European Association for 
Haemophilia and Allied Disorders (EAHAD) initiated a Coagulation 
Factor Variant Database Project with the aim of gathering together 
single gene variant databases involved in clinical bleeding disorders 
that would provide a single web portal to LSDBs for genes in haemo-
stasis. The LSDBs would share a common architecture making navi-
gation of the database(s) easier as well as providing greater support 
for maintenance of the sites.
2  | CUR ATION AND GOVERNANCE
The EAHAD Variant Database Project was established in 2011 and 
is administered by a Steering Group, a Curator Group and individual 
Variant Database Advisory Committees; further details of the com-
position of these groups can be found on the EAHAD Coagulation 
Factor Variant Database Project home page (dbs.eahad.org). Each 
individual variant database has a lead curator and a curator who are 
supported by further experts in the field. One of the important roles 
of the curators is to ensure that variants are correctly described 
with the correct nomenclature relative to the correct reference se-
quence. An increasingly important task of the curator(s) is also to 
suggest where possible the potential functional consequences of a 
variant. Current EAHAD curators are working as co-chairs or mem-
bers of relevant ClinGen Variant Curation Expert Panels (clini calge 
nome.org). ClinGen is an initiative to build a knowledge base on 
genes associated with disease and to assess likely pathogenicity of 
variants within a given gene. The variant curation process combines 
clinical, genetic, population and functional evidence with expert re-
view to classify variants according to ACMG/AMP guidelines. The 
results are deposited in an open access database (ClinVar; ncbi.nlm.
nih.gov/clinv ar/).
The availability of an up-to-date open access variant database 
is a crucial tool for diagnostic and research laboratories; therefore, 
there is free and unrestricted access to all the online EAHAD vari-
ant databases. However, in order to honour the legal requirements 
of medical/health information and data protection ensuring that no 
individuals can be identified from the data stored and distributed 
in the databases, no patient IDs or the geographical location of the 
submitting laboratory are publicly available (unless they are already 
in the public domain through published articles). However, these de-
tails are maintained off-line in a secure database to make it possible 
to identify individual patient records and their source if required. 
Further details of the EAHAD variant database policy can be found 
on the home page (dbs.eahad.org).
3  | NOMENCL ATURE
It is particularly important in molecular genetic analysis that there is no 
confusion resulting from differences in variant nomenclature between 
laboratories/publications. Many coagulation genes were cloned and in-
itially sequenced during the 1980s, prior to the introduction of stand-
ardized nomenclature. As a result, genes and proteins have their own 
idiosyncrasies of naming and numbering. This can lead to confusion in 
the laboratory, literature and diagnostic setting. The Human Genome 
Variation Society (HGVS) has devised an extensive scheme for nomen-
clature of sequence variants (varno men.hgvs.org8). To reduce confu-
sion, an International Society of Thrombosis and Haemostasis (ISTH) 
working group published recommendations that full adoption of stand-
ard gene names and of DNA and protein sequence variant numbering 
according to HGVS guidelines should be adopted for all genes/proteins 
in haemostasis.9 All variants described in the EAHAD databases there-
fore conform to HGVS guidelines and are reported in relation to refer-
ence sequences (RefSeq) maintained by the American National Centre 
for Biotechnology Information (NCBI). Variants are described using 
cDNA and protein reference sequences; however in future releases, 
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variants will also be described using a locus genomic reference (LRG) 
sequence. This description is currently available from the Leiden Open 
Variation Database (LOVD; lovd.nl) to which we mirror all variants 
described in the EAHAD database. Sequence variants differing from 
the reference sequence are denoted by a prefix, c. for cDNA and p. 
for amino acid variants. The A of the ATG initiator methionine is uti-
lized as the sequence start point +1 and similarly the first methionine 
is numbered +1. This differs from some legacy numbering of haemo-
stasis proteins where the signal peptide (and sometimes pro-peptide) 
was numbered negatively and amino acid numbering started from the 
beginning of the mature protein. Both HGVS and ‘Legacy’ numbering 
are provided for the F7, F8 and F9 databases. The CoagBase web page 
(coagb ase.org) provides information for coagulation factor genes in-
cluding gene names, RefSeq as well as an indication of the difference 
between legacy and HGVS amino acid numbering schemes.
4  | DATABA SE STRUC TURE
The databases (Table 1) are built on a common architecture using a 
MySQL platform, and their interface was developed using HTML, CSS, 
JavaScript, Perl and PHP. They are available at dbs.eahad.org. In order 
to encourage the ethos of data sharing and open access to resources, 
the variant data in the databases are shared with LOVD (lovd.nl10), 
which is a freely available gene-centred collection of DNA variant data.
The databases allow simple searches of variants based on nucle-
otide or amino acid numbering (HGVS and legacy), variant type or 
location within the gene. In addition, advanced search options allow 
further refinement of searches based on variant effect, protein do-
main, severity and inhibitor status (where known). A search returns the 
unique variants at the selected position in the gene or protein as a list 
with links where appropriate to in-depth analysis of the variation and 
anonymized patient information (Figure 1). Unlike other variant DBs, 
the EAHAD databases store and display all cases reported regardless 
of how many individual reports of the identical genetic variant have 
been reported, allowing users to survey phenotypic variability among 
dozens or even hundreds of cases with the same variant.
It is possible to visualize/export the data either as list of unique 
variants at the selected position, or as a multiple patient list showing 
all individuals with a particular variant at that position, allowing be-
tween-case comparisons to assess variability of presentation. This 
also allows the assessment of the frequency of reporting a particular 
variant; however, it should be noted that this frequency may be bi-
ased by extensive family studies, founder effects in certain ethnic 
groups and does not represent the frequency within the affected 
population. In addition, the database presents statistics and graphics 
on all the variants in the database by specific type of variant, by pro-
tein domain and by disease severity (Figure 2). There is also a variant 
map of all missense variants mapped onto the amino acid sequence 
of the protein.
Predicting whether or not a variant is pathogenic may not be 
straightforward, especially for synonymous and missense variants 
or for those occurring in intronic sequences or promoter regions 
of the gene. The databases provide access to in silico analyses that 
may be useful in the prediction of variant pathogenicity of missense 
variants using open access software packages (Table 2). The minor 
allele frequency (MAF) of variants in large population studies such 
as the Genome Aggregation Database (gnomAD; gnomad.broad 
insti tute.org11) is also provided and can be useful in assessing the 
predicted variant pathogenicity. Where a MAF is not presented, this 
indicates that this variant has not been identified in the data set and 
is a rare variant or in a region that is not read to an adequate depth 
in the control data sets. The structural consequence of a missense 
variant can also be visualized if an appropriate molecular model of 
the relevant protein structure is available. Finally, the evolutionary 
conservation of the amino acid sequence of the protein at the vari-
ant residue in closely related species (eg, chimpanzee, gorilla, gibbon, 
bushbaby and marmoset), or of closely related human proteins, can 
be inspected. While the use of in silico methods such as these can be 
extremely useful in predicting the severity of the amino acid change, 
these methods should not be relied on solely to assign pathogenicity.
5  | IDENTIFIC ATION OF VARIANTS
The databases have been built incorporating variants previously 
reported in databases for each of the relevant genes (Table 1). 
Additional variants were identified by searches of the Human Gene 
TA B L E  1   European Association for Haemophilia and Allied Disorders (EAHAD) variant databases
Gene Disorder EAHAD DB website LOVD DB website Contributing databases
F7 Factor VII deficiency f7-db.eahad.org datab ases.lovd.nl/share d/
genes /F7
MRC FVII mutation 
database5; UMD-F7 
database
F8 Haemophilia A f8-db.eahad.org datab ases.lovd.nl/share d/
genes /F8
The factor VIII structure 
and mutation resource site: 
HAMSTeRs; HADB2,4,18
F9 Haemophilia B f9-db.eahad.org lovd.nl/share d/genes /F9 Haemophilia B: database of 
point mutations and short 
additions and deletions19
VWF von Willebrand disease vwf-db.eahad.org datab ases.lovd.nl/share d/
genes /VWF
Sheffield VWFdb20
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Mutation Database (hgmd.cf.ac.uk12), literature searches and direct 
submission by reporting laboratories. All variants incorporated into 
the new databases were verified for accuracy, and HGVS nomen-
clature was generated and checked with Mutalyzer (mutal yzer.nl13). 
Each variant was linked to the original publication describing the 
variant(s). Finally, any duplicated cases were removed. Identifying 
duplicate accounts of the same patient can be problematic as multi-
ple published accounts of the same cases can occur and there may 
be no explicit reference to previous publications and/or the use of 
a unique laboratory patient identifier. If there was any doubt over 
duplication of reporting an individual, then both records were main-
tained in the database. Future updates to the databases will be made 
F I G U R E  1   Screenshot of the in-depth variant analysis following a search of the Factor VIII Gene Variant Database for variants in codon 
415 (legacy 396) showing the predicted consequence of variant c.1244C>T (p.Ala415Val) using in silico prediction programmes, structural 
implications and location of the variant within the FVIII structure and finally multiple amino acid sequence alignments across primates. 
Further multiple sequence alignments are available from the AA Alignments tab at the top of the page. The case information for this variant 
is also shown demonstrating the range of laboratory data and ascribed bleeding severity in eight reported individuals
F I G U R E  2   Screenshot of the database 
statistics available on the Factor VIII 
Gene Variant Database f8-db.eahad.
org/statistics.html.php illustrating the 
percentage of: variants by type; variants 
within specific protein domains; and cases 
by disease severity. Similar information is 
available on the factor IX and VII websites
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on a yearly basis by continued literature searches. Direct submission 
of variant cases to EAHAD database curators is highly encouraged, 
and electronic submission forms are available on the EAHAD Variant 
Database Project home page (dbs.eahad.org). All new submissions 
are validated by the expert curator(s) before they are added to the 
relevant database.
6  | UTILIT Y OF E AHAD DATABA SES
It is recognized that the availability of standardized, validated DNA 
variant and phenotypic data is a crucial tool for diagnostic and re-
search laboratories in the accurate classification of disease sever-
ity, and in order to make assessments of likely pathogenicity. The 
establishment of the EAHAD Coagulation Factor Variant Database 
Project has enabled the development of a single platform for gene-
specific variant databases for the rare bleeding disorders. It has al-
lowed the development of three new online databases for variants 
in the genes encoding FVII, FVIII and FIX and links with the existing 
database for variants in the gene for VWF. One of the important 
advances has been the conversion of legacy descriptions of variant 
data to a standardized nomenclature as recommended by the HGVS 
and the use of reference sequences to allow unambiguous mapping 
of the positions of variants. The new databases have been updated 
substantially with new variants. The databases for F7 (f7-db.eahad.
org), F8 (f8-db.eahad.org) and F9 (f9-db.eahad.org) currently have 
221, 2015 and 2591 unique variants in the respective genes cor-
responding to 728, 8424 and 3713 individual cases (accessed 18 July 
2019).
6.1 | Assigning pathogenicity
Variant classification is central to the utility of molecular genetic 
diagnostics in clinical practice; however, predicting whether gene 
variants are pathogenic is not straightforward. While nonsense 
and frameshifting small and large rearrangements are accepted as 
pathogenic in most genes, the prediction of the effects of syn-
onymous and missense variants or those located in introns or in 
promoter regions of genes is problematic. Classification should be 
evidence-based, objective and systematic. Guidelines to establish 
a framework for variant classification have recently been pub-
lished14,15 with the aim of evaluating evidence in a systematic hier-
archical manner evaluating as follows: population data; expected 
effect of the variant on the gene product; clinical data; and pre-
dictive data derived from functional experiments or mutagenesis. 
The databases do not currently assign pathogenicity classification 
for individual variants but in future will link directly to ClinVar 
(ncbi.nlm.nih.gov/clinvar) which is an open access database that 
reports curated information and likely pathogenicity on gene vari-
ants. EAHAD curators are working as co-chairs or members of rel-
evant curation panels that input into ClinVar.
Evaluation of variant frequencies from large population data 
sets can provide strong evidence that a variant is benign or can 
identify one that is sufficiently rare to be considered a candidate 
pathogenic variant. The EAHAD variant databases link to the 
MAF of a variant in gnomAD database (based on exome and ge-
nomes of 141 456 individuals11). MAF values >0.05 in a control 
population may be considered stand-alone support for a benign 
interpretation. However, many benign variants are private and 
therefore absence or a low allele frequency is not considered suf-
ficient evidence for pathogenicity. The expected allele frequency 
for haemophilia A would be between 0.0001 (one in 10 000) and 
0.00005 (one in 20 000). The most frequent allele associated with 
reduced factor VIII antigen and activity levels (20%) and a mild 
bleeding phenotype is p.Val64Gly with a MAF of 0.000228. For F9, 
the most frequent allele associated with reduced FIX activity and a 
mild bleeding phenotype is p.Glu323Lys with a MAF of 0.0009748. 
However, variation in F7 is more complex with common vari-
ants (p.Arg314Gln, MAF = 0.1341; c.-325_-324insCCTATATCCT, 
Program name




Combines the biophysical characteristics of 
amino acids and protein multiple sequence 
alignments to predict where missense 
substitutions in genes of interest fall in 




Predicts possible impact of an amino acid 
substitution on the structure and function 
of the protein based on physical and 
evolutionary conservation
sift sift.jcvi.org/;23 Uses sequence alignments to score the 




Uses pairwise sequence alignment scores 
to generate predictions for amino acid 
substitutions in protein sequence homolog
TA B L E  2   In silico tools used to predict 
the consequence of missense variants
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MAF = 0.1632) that are not pathogenic in themselves but are as-
sociated with substantially reduced levels of FVII and therefore 
when co-inherited with other variants can have a significant im-
pact on the overall phenotype.
The databases do not contain detailed clinical information but 
provide information on the ascribed severity of bleeding based on 
the submitter's observations when available. Where available, lab-
oratory data from individual cases have been included. There are 
a number of validated assays that measure functional activity or 
quantify plasma concentrations of coagulation factors. This type 
of data straddles the boundary between clinical phenotype and 
in vitro functional data but must be interpreted in the context of 
the pathophysiological levels associated with particular diseases. 
For example, in the case of FVII activity it is essential to use only 
data obtained using human tissue factor (TF; thromboplastin) as 
the trigger for coagulation. The use of TF from animal sources or 
recombinant versions thereof may result in discrepant and mis-
leading in vitro results that are inconsistent with assays performed 
with human TF and the bleeding phenotype of the individual con-
cerned.16 Thus, the species of TF (unknown, rabbit or human) used 
to generate the FVII activity values (FVII:C) presented in the F7 
variant database are indicated where known. Similarly, it is well 
recognized that certain missense variants in F8 are associated with 
‘assay discrepancy’ such that the values obtained with two-stage 
or chromogenic assays are substantially lower than the result with 
the one-stage assay. The opposite effect with a lower one-stage 
result is much less common but may also occur. This is of clinical 
significance as reliance on one assay might lead to a diagnosis of 
mild haemophilia A being missed. Variants known to be associated 
with ‘assay discrepancy’ are labelled as such in the database and 
on clinical reports. Furthermore, by collecting these variants to-
gether in the database insights into their localization in the FVIII 
tertiary structure have been gained which allows prediction of 
whether a novel variant might have a similar effect.
It should however be noted that discrepancies in the laboratory 
value or ascribed clinical severity between cases can arise due to 
differences in classification schemes used in different centres, dif-
ferent assays and standards used in reporting residual activity and 
finally the reported level may reflect a trough level rather than the 
true baseline in patients on prophylaxis. A variant is more likely 
to be pathogenic if it has an impact on the expression or function 
of the gene product. We have used in silico programmes (Table 2) 
to predict the likely impact of missense variants on the resultant 
protein based on the biophysical properties of the variant and the 
evolutionary conservation of the amino acid residue. Prediction of 
non-coding variants is more problematic. Whereas variants in the 
invariant AG/GT dinucleotides located at the 5′ and 3′ intron-exon 
boundaries are highly likely to result in a pathogenic phenotype, 
it is much more difficult to predict the consequence of variants in 
promoter or intronic sequences. Multiple software programs have 
been developed to predict the possible effect of a variant on RNA 
splicing. Although not sufficient to establish clinical relevance, 
splice-site prediction can be very helpful to predict those variants 
that may merit further investigation. These programs have been 
shown to be accurate in predicting whether an effect on splicing 
is likely.17
Although predictions from in silico tools and biochemical/func-
tional evidence are useful in predicting the severity of amino acid 
substitutions, they should not be used to assign pathogenicity in the 
absence of other supporting data. In particular, supporting clinical 
observations should have primacy as clinical data describe human 
disease directly, whereas quantitative and qualitative effects are only 
relevant to the disease as it correlates with disease pathophysiology.
6.2 | Future developments
We support the ethos of open access and data sharing, and we en-
courage researchers and clinicians to contribute to the project by 
submitting their variant data to the relevant databases via the sub-
mission forms on the EAHAD Coagulation Factor Variant Project 
home page (dbs.eahad.org). We have made all reasonable efforts 
to ensure that the information contained in the databases and dis-
played on the web pages is accurate; however, the database may 
contain errors and we would be grateful if users could inform us of 
any that they find.
The development of a common database architecture will 
allow other coagulation factor variant databases to be developed. 
Databases for F10 and F11 are planned as well as FGA, FGB and 
FGG, responsible for FX, FXI and fibrinogen deficiency, respectively. 
If you would like to contribute to the project by either developing 
future databases in the field or by offering your services as a curator, 
please contact us.
7  | CONCLUSION
The analysis of genotype-phenotype relationships in rare dis-
eases such as the bleeding disorders associated with deficiencies 
in FVII, FVIII, FIX and VWF requires international collaboration 
and standardized reporting. The establishment of the EAHAD 
Coagulation Factor Variant Database Project has generated a 
common database architecture and web-based platform that 
includes analytical tools to assess the structure/function con-
sequence of variants. This has allowed the implementation of 
updated variant databases for F7, F8, F9 and VWF. The variant 
databases will be an invaluable resource for scientists and clini-
cians in the field of haemostasis.
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